tau imaging news gives memory clinic patients a clearer path: blood tests can help prioritize who needs PET, and a newer tau PET can stage tangles earlier. What remains limited is diagnosis itself, because scans and blood markers guide workups but do not replace clinical judgment. Tau imaging means pictures of tau tangles, twisted tau proteins that build up in brain cells in Alzheimer's disease. A tau PET scan uses a tracer to make tangles visible, while blood tests measure tau-related fragments that track with that buildup.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What is new in tau PET?
- Where do blood tests fit before a scan?
- Can a blood test measure tangle burden?
- What should patients ask at a memory visit?
What is new in tau PET?
The FDA approved TAUKLARIFY, also called florquinitau F-18 or MK-6240, on Aug. 14, 2026, for brain PET in cognitively impaired adults being evaluated for Alzheimer's to identify tau tangle pathology, as reported by Lantheus Holdings in the FDA approval notice. That indication places tau PET in diagnostic workups for memory symptoms, not broad screening.
A head-to-head study scanned the same people with Tauvid and MK-6240. MK-6240 detected tangles earlier and staged disease more accurately, according to Being Patient reporting on The Lancet in the head-to-head study report. Earlier detection matters because tangle stage helps explain symptoms and plan care.
Where do blood tests fit before a scan?
Plasma p-tau217, a blood marker tied to Alzheimer's pathology, showed strong rule-in performance in 789 cognitively unimpaired participants, with positive predictive values over 83% versus amyloid PET, according to NeurologyLive in the AAIC p-tau217 analysis. A strong rule-in result means a positive blood test often points toward underlying pathology and closer follow-up.
Other data support using blood first, then PET for detail. Plasma p-tau217 was noninferior to amyloid PET quantitation for early pathology, and very high levels carried 38% five-year progression risk versus 24% for high levels, according to Psychiatric Times in the biomarker testing summary. For patients, that pattern favors blood-first triage with PET reserved for staging.
Can a blood test measure tangle burden?
A blood assay for eMTBR-tau243 correlates with middle- and late-stage tangle burden. It may offer a cheaper way to estimate tangle load than tau PET.
That use is practical for follow-up decisions. A clinic might use p-tau217 to flag likely Alzheimer's pathology, then use eMTBR-tau243 or tau PET to judge how far tangle buildup has advanced. Blood cannot show where tangles sit in the brain, so imaging keeps a role when location and stage affect care.
What should patients ask at a memory visit?
Ask whether symptoms meet the clinic's criteria for Alzheimer's evaluation. Ask whether a blood test could come first, what a result would change, and whether PET would still add staging information. Bring a medication list, symptom timeline, and a family member who sees daily function.
Also ask about other causes of memory change, because tau results sit alongside history, exams, thinking tests, and other labs or scans. TAUKLARIFY's label states safety and effectiveness are not established for non-Alzheimer's tauopathies, a negative scan does not exclude tau pathology, and a positive scan alone does not establish Alzheimer's. Keep that boundary in mind before seeking a scan on your own.
- Am I being evaluated for Alzheimer's after cognitive impairment?
- Would a p-tau217 result change the next test or referral?
- Would tau PET change diagnosis, staging, treatment access, or planning?
- What does a positive or negative result not prove in my case?
You Might Also Like
- Tauklarify Imaging for Alzheimer’s Tau Tangles in 2026: What Is Established and What Remains Uncertain for Memory Clinic Patients
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: What Is Established and What Remains Uncertain for Memory Clinic Patients
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: What Is Established and What Remains Uncertain for Memory Clinic Patients
